Saama Technologies and ICON have partnered to accelerate the use of Real World Evidence (RWE) across the product lifecycle and drive mission critical decisions for medical affairs, reimbursement and commercialization functions.
Biopharmaceutical, medical device and diagnostic companies are seeking comprehensive RWE technology solutions that can support an array of RWE applications across the enterprise. Through this partnership, ICON brings real world data (RWD) strategy and platform deployment expertise to complement Saama’s experience in utilizing applications such as Natural Language Processing, Machine Learning and advanced Data Visualization tools.
“Saama is very excited about our partnership with ICON, which further expands our new Life Science Ecosystem,” said Murali Krishnam, VP Strategic Partnerships and Alliances of Saama. “Saama’s Artificial Intelligence-based analytics platform, combined with ICON’s Real World Evidence, Strategy and Analytic (RWESA) services, will help biopharmaceutical, medical device and diagnostics companies rapidly deploy a RWE-generating platform. This will support greater efficiencies in drug development, providing the RWE needed to inform medical affairs, regulatory and reimbursement decisions and underscoring the value of the medical technology to patients and providers.”
Saama’s Life Science Analytics Cloud (LSAC) integrates multiple sources of structured, unstructured and real-time data to optimize clinical and commercialization processes for deployment in less than 90 days, thus securing better business outcomes faster. Additionally, LSAC further lowers the total cost of platform ownership significantly for continuous RWE generation and for managing evolving business needs. This approach integrates with ICON’s Real World Intelligence approach to combine RWD and expertise in answering important questions on patient experience, market access requirements, strategic evidence planning and roadmap development.